We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Fertility and prognosis assessment between bleomycin/etoposide/cisplatin and paclitaxel/carboplatin chemotherapy regimens in the conservative treatment of malignant ovarian germ cell tumors: a multicenter and retrospective study.
- Authors
Ran Chu; Penglin Liu; Jingying Chen; Xiaodong Cheng; Kezhen Li; Yanci Che; Jianliu Wang; Li Li; Xi Zhang; Shu Yao; Li Song; Ying Zhao; Changzhen Huang; Ying Xue; Xiyu Pan; Junting Li; Zhongshao Chen; Jie Jiang; Beihua Kong; Kun Song
- Abstract
Objective: To evaluate the impact of bleomycin/etoposide/cisplatin (BEP) and paclitaxel/carboplatin (PC) chemotherapy regimens on the fertility and prognostic outcomes in malignant ovarian germ cell tumor (MOGCT) patients who underwent fertility-sparing surgery (FSS). Methods: A propensity score matching algorithm was performed between the BEP and PC groups. The X2 test and the Kaplan-Meier method were used to compare the fertility outcome, disease-free survival (DFS) and overall survival (OS). The Cox proportional hazards regression analysis was used to identify risk factor of DFS. Results: We included 213 patients, 185 (86.9%) underwent BEP chemotherapy, and 28 (13.1%) underwent PC chemotherapy. The median age was 22 years (range, 8-44 years), and the median follow-up period was 63 months (range, 2-191 months). Fifty-one (29.3%) patients had a pregnancy plan, and 35 (85.4%) delivered successfully. In the before and after propensity score matching cohorts, there were no significant differences in spontaneous abortion, selective termination of pregnancy, during-pregnancy status, and live birth between the BEP and PC groups (p>0.05). Fourteen (6.6%) patients experienced recurrence, including 11 (5.9%) in the BEP group and 3 (10.7%) in the PC group. Four (1.9%) patients in the BEP group died. Kaplan-Meier analysis revealed no significant differences in DFS (p=0.328) and OS (p=0.446) between the BEP and PC groups, and the same survival results were observed in the after matching cohort. Conclusion: The PC regimen is as safe as the BEP regimen for MOGCT patients with fertility preservation treatment, and no differences were observed in fertility and clinical prognosis.
- Subjects
GERM cell tumors; CONSERVATIVE treatment; ABORTION; FERTILITY; PACLITAXEL; BLEOMYCIN
- Publication
Journal of Gynecologic Oncology, 2023, Vol 34, Issue 2, p1
- ISSN
2005-0380
- Publication type
Article
- DOI
10.3802/jgo.2023.34.e12